ThermoTraumaPort’s Nomination from the Prix Galien UK Awards: Healthcare Innovation Recognised
- libby1490
- Jun 10
- 2 min read
In the world of healthcare innovation, few accolades shine brighter than the Prix Galien Awards, often described as the ‘Nobel Prize’ for life sciences. This year, ThermoTraumaPort (TTP) — a Norfolk-based medical technology pioneer — has been shortlisted for Best Medical Technology at the 2025 Prix Galien UK Awards.
For a company founded just seven years ago by visionary Mary Anne Cordeiro, this nomination is more than recognition — it’s the culmination of dedication, disruptive thinking, and meaningful collaboration. A crucial part of her journey to success has been the support of Anglia Capital Group, whose belief in TTP’s mission helped fuel their growth through private Angel investment.
Transforming Trauma Care
Founded in 2018, TTP was born from a bold mission: to revolutionize emergency care by making trauma and critical patient transfers safer, easier, and more secure.
Their flagship device — also called ThermoTraumaPort — is an innovative device that directly addresses major challenges in emergency medicine. It combines battery-powered active warming to prevent hypothermia, a radiolucent foam mattress suitable for imaging (such as CT scans), and a single-use disposable cover that reduces the risk of cross-infection.
Alongside clinicians at East Anglian Air Ambulance (EAAA), Dr. Jeremy Mauger, Pre-hospital Consultant and co-inventor, recognised that trauma patients were often moved multiple times during treatment, risking further injury and significant loss of body heat — further compromising survival chances.
Now, after seven years of rigorous development, including clinical trials, patent filings in the US and Europe, and various partnerships including University Hospital of Birmingham, TTP is set to make a real difference not only across the UK but internationally.
Recognition at the Prix Galien UK Awards
Being shortlisted for the Prix Galien UK Awards places TTP in the company of world-class innovators. This recognition underscores the device’s potential to save lives and transform trauma care worldwide.
But great ideas need support to succeed — and that’s where Anglia Capital Group came in.
Anglia Capital Group’s Role in TTP’s Success
In September 2024, TTP were presented to Anglia Capital Group, impressing investors with:
An evident, urgent need in trauma care
Positive early-stage trial results
A clear pathway to regulatory approval and market adoption
Strong industry connections
A coherent, scalable financial plan
Three Angels went on to invest as part of a £250,000 SEIS-eligible round. Being more than just financial backers, they brought valuable knowledge in medtech, and wider business and investing experience.
“We are delighted to see a Norfolk-based start-up working with customers across the globe. This investment will allow ThermoTraumaPort to move ahead with their ambitious plans for growth.”
Laura Hood, Operations Director at Anglia Capital Group.
Looking Ahead
With global potential, including planned launches in the US for military and emergency use, TTP’s story is just beginning. Whether or not they take home the top prize at the 2025 Prix Galien UK Awards, the recognition signals a major win for Founder, Inventor and CEO, Mary Anne Cordeiro, who leads a team of collaborators and product design and manufacturing specialists — and for the partnership between TTP and Anglia Capital Group.